HeartMate 3 Breakthrough, A New Era in Aspirin Free Heart Failure Treatment

Abbott’s ARIES Trial Findings Aspirin Free Heart Failure Treatment

Abbott, a leading healthcare company headquartered in Abbott Park, Illinois, has recently unveiled groundbreaking findings from the ARIES trial, providing a significant leap forward in the management of advanced heart failure patients using their HeartMate 3TM heart pump. The late-breaking data, presented on November 13, 2023, challenges established norms, suggesting that an aspirin-free medication regimen can offer substantial benefits to individuals with this life-saving heart pump.


Introducing the HeartMate 3™ LVAD featuring cutting-edge Full MagLev™ Flow Technology, a revolutionary mechanical circulatory support pump that has propelled the LVAD therapy landscape to new heights. Renowned for its innovation and exceptional clinical outcomes, the HeartMate 3™ LVAD has emerged as the benchmark, bringing about significant improvements in the lives of your patients.

At the heart of this advancement lies the Full MagLev Flow Technology integrated into the pump, ensuring a gentle and sophisticated approach to blood handling. This groundbreaking feature aims to minimize complications and mitigate hemocompatibility-related adverse events, marking a substantial leap forward in enhancing the overall patient experience.

Designed to cater to the needs of advanced heart failure patients requiring either short- or long-term mechanical circulatory support, the HeartMate 3™ LVAD stands as a beacon of progress in the field, symbolizing a commitment to excellence and improved outcomes for individuals facing complex cardiovascular challenges.

The ARIES HM3 Clinical Trial

The ARIES-HM3 trial outcomes revealed that for patients with advanced heart failure (HF) receiving a HeartMate 3 LVAD and treated with a VKA anticoagulant, the use of a placebo was found to be equally effective, in terms of the combined occurrence of bleeding and thrombotic events at the one-year mark, when compared to daily aspirin.

Trial Objective: The primary goal of the ARIES-HM3 trial was to assess the noninferiority of antithrombotic therapy with a vitamin K antagonist (VKA) alone, in comparison to a combination approach involving VKA and aspirin. This evaluation specifically targeted individuals who had undergone the implantation of a HeartMate 3 (HM3) left ventricular assist device (LVAD) as part of their treatment for advanced heart failure (HF).

RELATED ARTICLE AHA 23 Late-Breaker Discussion: The ARIES HM3 Clinical Trial

Conducted from July 2020 to September 2022 across 51 international centers, the ARIES trial stands out as the first-ever international, placebo-controlled, randomized clinical study examining the safety and bleeding outcomes associated with an aspirin-free approach for those with the left ventricular assist device (LVAD) known as HeartMate 3.

Article Description:

At the core of this groundbreaking research is Abbott’s HeartMate 3, which has played a crucial role in supporting over 30,000 individuals worldwide facing advanced heart failure. The recent findings, disclosed by Abbott on November 13, 2023, provide a transformative perspective on medication regimens for these patients.

The trial data unveiled that individuals with advanced heart failure using the HeartMate 3 heart pump, and not incorporating aspirin into their anticoagulant treatment, encountered fewer bleeding complications. Strikingly, these patients also demonstrated a reduction in hospital visits when contrasted with those adhering to a daily aspirin routine post-implant.

A pivotal aspect of the ARIES trial lies in its potential to revolutionize the management of patients with a HeartMate 3 heart pump. Conceived to evaluate the safety and effectiveness of an aspirin-free medication plan, the trial introduces a paradigm shift in the traditional approach to antithrombotic treatment for these individuals.

Presented during a late-breaking session at the 2023 American Heart Association’s Scientific Sessions in Philadelphia, the ARIES trial’s data provided groundbreaking insights. Concurrently, the results were published in The Journal of the American Medical Association, enhancing the credibility of the findings.

Dr. Mandeep R. Mehra, Executive Director of the Center for Advanced Heart Disease at Brigham and Women’s Hospital in Boston, Massachusetts, expressed excitement about the compelling nature of the data. He highlighted that avoiding aspirin, as indicated by the ARIES trial, is akin to introducing a novel device to the market, emphasizing the potential for a substantial shift in patient management strategies.

Encompassing over 600 patients, the trial illustrated that HeartMate 3 patients not receiving aspirin but adhering to the standard post-implant vitamin-K antagonist (VKA) treatment regimen achieved non-inferiority compared to aspirin consumers. This non-aspirin group experienced an impressive 47% reduction in hospitalization days, attributed to nearly a 40% decrease in bleeding events compared to their aspirin-consuming counterparts.

Despite the HeartMate 3 demonstrating generally lower complication rates compared to earlier-generation heart pumps, bleeding remains a significant concern, leading to rehospitalizations. The ARIES trial has the potential to revolutionize patient care by showcasing a reduction in bleeding events for patients not taking aspirin, presenting an opportunity for a paradigm shift in the management of individuals with a HeartMate 3.

FOR MORE MEDICAL RESEARCHED ARTICLES Improving Renal Function,The Impact of Axillary Mechanical Circulatory Support

The influence of the ARIES trial stretches beyond medical consequences to encompass economic considerations. In addition to the decreases in bleeding incidents and hospital visits related to bleeding issues, the trial uncovered noteworthy cost savings for heart failure patients who opted not to use aspirin post-implantation of an Abbott HeartMate 3 pump. One year after receiving the device, there was a considerable 41% decrease in estimated costs associated with bleeding events. Crucially, this same group exhibited no heightened risk of developing thrombosis, a blood clot that increases the likelihood of stroke.

Dr. Robert Kormos, Divisional Vice President of Global Medical Affairs at Abbott’s heart failure business, underscored the potential impact on patient lives. He highlighted that the ARIES trial approximates that abstaining from aspirin for every 100 individuals with the HeartMate 3 could prevent nearly 15 major bleeding events within the first year of device use, affording patients more precious moments with their loved ones and enabling them to lead a more fulfilling life.

It’s crucial to highlight that the ARIES trial’s anticoagulation regimen changes have not been approved by the U.S. Food and Drug Administration (FDA) at this time, underscoring the importance of continued research and regulatory scrutiny in translating these findings into clinical practice.

In conclusion, Abbott’s ARIES trial represents a significant advancement in the field of heart failure management, challenging established practices and providing a potential shift in the treatment paradigm for individuals with the HeartMate 3 heart pump. The implications of these findings extend beyond medical benefits, encompassing economic considerations and paving the way for further innovations in the care of advanced heart failure patients.

Related posts
BreathingHealth TipsMEDICAL RESEARCH

Understanding the Surprising Relationship Between Cleaner Air and Increased Legionnaires Disease Cases

Exploring the Unexpected Surge in Legionnaires Disease Cases Recent research conducted by…
Read more
Health TipsBODY BUILDINGtrending

Drostanolone Propionate: The Game-Changing Elixir in Bodybuilding

Drostanolone Propionate in Bodybuilding: A Comprehensive Guide to Success Embarking on the…
Read more
Health TipsEye care

Digital Eye Care: Navigating Screen Time for Healthy Eyes

Lifestyle Adjustments for Healthy Eyesight Eye health often takes a back seat for some…
Read more

Leave a Reply

Your email address will not be published. Required fields are marked *